sales and revenue examples, page-5

Thx Lopez. I'm being a bit tougher on biotechs these days and trying to work out what will be the next SRX over the years ahead. I think the key to replicating that is trying to work out when to get in. The catalyst with SRX was getting coverage and inclusion in their funds from the big guys like UBS, Perpetual and Macquarie. That doesn't seem to happen until there is clear evidence of sales and preferably rapidly escalating sales figures. Knowing the potential of these kind of companies like QRX is important, so that you recognise that as soon as the environment appears right then it's time to buy up big. So I'm waiting and monitoring.